MYOM2 and prostate cancer: In August 2016, He was an 85-year-old man at the moment of diagnosis with CML and prostate cancer and after 61-month treatment with imatinib he developed another primary cancer, multiple myeloma, based on the presence of serum M-protein, abnormal plasma cells in the bone marrow, and CRAB criteria.